An Ancillary Study of Patients With Advanced Stage Serous Carcinoma of the Ovary Treated on GOG Protocol 158: A Survival Analysis Based on Reclassification to a Two-tier Grading System
The purpose of this study is to describe the progression-free and overall survival of
patients treated on GOG protocol 158 when their tumors are reclassified into a two-tier
grading system. Although no universal grading system exists, Malpica et al. have recently
published data on a clinically meaningful two-tier grading system for serous ovarian
carcinoma (Malpica et al., American Journal of Surgical Pathology, 2004). Tumor grade has
been shown to be an important prognostic factor in women with epithelial ovarian cancer,
especially in early stage carcinomas. While there is less consensus regarding the prognostic
significance of grade in late stage tumors, researchers have noted that patients with
low-grade advanced disease may have a longer survival than those with high-grade lesions
(Bodurka-Bevers et al., Gynecologic Oncology, 2000).
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Reclassification of histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system.
2 Years
No
Diane C. Bodurka, MD, BS
Principal Investigator
UT MD Anderson Cancer Center
United States: Institutional Review Board
2007-0509
NCT00837993
August 2007
December 2012
Name | Location |
---|---|
UT MD Anderson Cancer Center | Houston, Texas 77030 |